Table 3.
Characteristics of hyaluronic acid (HA) silica nanomedicines.
| Bond | Pore | Cargo | Drug Loading Content (%) | Responsive Stimuli | Therapy Method | Size (nm) | Surface Charge (mV) | HA MW (kDa) | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| Amide | O | Dox | 1.2 | X | Chemo | 70–100 | −18.8 | 200 | [64] |
| Electrostatic interaction | O | TH287, MDR1 siRNA | 8.91 | X | Chemo | 184 | −18.4 | [72] | |
| Amide | O | 6-Mercapto-purine | GSH | Chemo | 80 | −25.5–−27.9 | 10 | [73] | |
| Amide | O | CPT | 0.96 | X | Chemo | 100 | −14.9 | 18 | [75] |
| Amide | O | Dox | 0.01 | HAdase | Chemo | 232 | −30 | 100 | [65] |
| Amide | X | 5-Fluoro-uracil | 15 | X | Chemo | 138 | 35 | [69] |
GSH: Glutathione; Chemo: Chemotherapy; Dox: Doxorubicin; CPT: Camptothecin.